- Home
- XFOR vs RMBI Comparison
XFOR vs RMBI Comparison
Compare XFOR & RMBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- RMBI
- Stock Information
- Founded
- XFOR 2014
- RMBI 1887
- Country
- XFOR United States
- RMBI United States
- Employees
- XFOR N/A
- RMBI N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- RMBI Major Banks
- Sector
- XFOR Health Care
- RMBI Finance
- Exchange
- XFOR Nasdaq
- RMBI Nasdaq
- Market Cap
- XFOR 118.4M
- RMBI 148.9M
- IPO Year
- XFOR N/A
- RMBI 2019
- Fundamental
- Price
- XFOR $3.37
- RMBI $14.00
- Analyst Decision
- XFOR Strong Buy
- RMBI
- Analyst Count
- XFOR 3
- RMBI 0
- Target Price
- XFOR $72.33
- RMBI N/A
- AVG Volume (30 Days)
- XFOR 146.4K
- RMBI 37.1K
- Earning Date
- XFOR 05-01-2025
- RMBI 04-24-2025
- Dividend Yield
- XFOR N/A
- RMBI 4.29%
- EPS Growth
- XFOR N/A
- RMBI 2.54
- EPS
- XFOR 2.16
- RMBI 0.89
- Revenue
- XFOR $31,364,000.00
- RMBI $42,825,048.00
- Revenue This Year
- XFOR $355.69
- RMBI N/A
- Revenue Next Year
- XFOR $140.28
- RMBI N/A
- P/E Ratio
- XFOR $1.56
- RMBI $15.72
- Revenue Growth
- XFOR N/A
- RMBI 2.64
- 52 Week Low
- XFOR $3.05
- RMBI $10.88
- 52 Week High
- XFOR $34.20
- RMBI $15.15
- Technical
- Relative Strength Index (RSI)
- XFOR 22.18
- RMBI 59.16
- Support Level
- XFOR $3.05
- RMBI $13.74
- Resistance Level
- XFOR $3.41
- RMBI $14.30
- Average True Range (ATR)
- XFOR 0.62
- RMBI 0.47
- MACD
- XFOR -0.02
- RMBI 0.02
- Stochastic Oscillator
- XFOR 8.94
- RMBI 76.19
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About RMBI Richmond Mutual Bancorporation Inc.
Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans. The company has one reportable segment which is Community Banking.